Day: May 4, 2023

– Petosemtamab clinical update presented at the American Association of Cancer Research (AACR) Annual Meeting 2023– Petosemtamab end-of-phase meeting with U.S. Food & Drug Administration provides clarity to potential registration path in head and neck squamous cell carcinoma (HNSCC)– Petosemtamab update planned for Q3 2023 on potential registrational path in HNSCC– Based on the Company’s current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into second half 2025 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the...

Hosting a Webinar on Friday, May 5, 2023, at 9:00 A.M. Eastern Time; Unveiling New Developments Powered by its Generative AI Technology LITTLE ROCK, Ark., May 04, 2023 (GLOBE NEWSWIRE) — Inuvo, Inc. (NYSE American: INUV), a leading provider of marketing technology, powered by artificial intelligence (AI) that serves brands and agencies, today provided a business update, and announced its financial results for the first quarter ended March 31, 2023. Richard Howe, CEO of Inuvo, stated, “The Company had a strong fiscal 2022, growing 26.5% year-over-year to $76.5 million. As expected, and discussed on our March year-end call, we started 2023 lower compared with the prior year because of a softening in demand for advertising and the loss of a client. Nevertheless, we delivered $11.8 million of revenue in the first quarter, a seasonally...

For the quarter ended March 31, 2023Record net sales of $2.233 billion, up 2.9% sequentially and up 21.1% from the year ago quarter. The midpoint of our guidance provided on February 2, 2023 was net sales of $2.224 billion. On a GAAP basis: record gross margin of 68.0%; record operating income of $848.0 million and a record 38.0% of net sales; record net income of $604.0 million; and record EPS of $1.09 per diluted share. Our guidance provided on February 2, 2023 was for GAAP EPS of $1.07 to $1.09 per diluted share. On a Non-GAAP basis: record gross margin of 68.3%; record operating income of $1.064 billion and a record 47.6% of net sales; record net income of $907.8 million and record EPS of $1.64 per diluted share. Our guidance provided on February 2, 2023 was for Non-GAAP EPS of $1.61 to $1.63 per diluted share. Paid down $153.0...

Quarterly revenue of $1.126 billion; GAAP EPS of $2.02 and adjusted EPS of $2.49 DALLAS, May 04, 2023 (GLOBE NEWSWIRE) — AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its first quarter 2023 financial results. Financial highlights are as follows: Dollars in millions, except per share amounts.  Q1 2023 % Change Q1 2022Revenue $1,126.2 (27%)Gross profit $368.8 (26%)Net income $84.1 (42%)GAAP diluted EPS $2.02 (35%)Adjusted diluted EPS* $2.49 (29%)Adjusted EBITDA* $179.6 (30%)* See “Non-GAAP Measures” below for a discussion of our use of non-GAAP items and the table entitled “Non-GAAP Reconciliation Tables” for a reconciliation of non-GAAP items. Business HighlightsHealthcare organizations...

SAN FRANCISCO, May 04, 2023 (GLOBE NEWSWIRE) — Dolby Laboratories, Inc. (NYSE:DLB) today announced the company’s financial results for the second quarter of fiscal 2023. “In the first half of the year, we continued to bring Dolby Atmos and Dolby Vision to more consumers across our movies and TV, music and user-generated content ecosystems,” said Kevin Yeaman, President and CEO, Dolby Laboratories. “We remain focused on our long-term growth opportunities and bringing Dolby to all the ways people experience their content.” Second Quarter Fiscal 2023 Financial HighlightsTotal revenue was $375.9 million, compared to $334.4 million for the second quarter of fiscal 2022. GAAP net income was $95.7 million, or $0.98 per diluted share, compared to GAAP net income of $36.7 million, or $0.36 per diluted share,...

AUDUBON, Pa., May 04, 2023 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2023.Worldwide net sales were $276.7 million, an increase of 20.0%, or 21.0% on a constant currency basis GAAP net income for the quarter was $49.1 million GAAP diluted earnings per share (“EPS”) was $0.48 and non-GAAP diluted EPS was $0.53 Non-GAAP adjusted EBITDA was $85.1 million, or 30.8% of net sales“Globus achieved a record quarter, delivering our highest quarterly revenue yet of $277 million, an increase of 21% over the first quarter of 2022 on a constant currency basis. Non-GAAP EPS was $0.53, an increase of 25% as earnings grew faster than sales due to operational efficiencies and disciplined spending,” said Dan Scavilla,...

JACKSONVILLE, Fla., May 04, 2023 (GLOBE NEWSWIRE) — Regency Centers Corporation (“Regency” or the “Company”) (Nasdaq: REG) today reported financial and operating results for the period ended March 31, 2023 and provided updated 2023 earnings guidance. For the three months ended March 31, 2023 and 2022, Net Income was $0.57 per diluted share and $1.14 per diluted share, respectively. First Quarter 2023 HighlightsReported Nareit FFO of $1.08 per diluted share and Core Operating Earnings of $1.03 per diluted share for the first quarter Raised 2023 Nareit FFO guidance to a range of $4.07 to $4.15 per diluted share and 2023 Core Operating Earnings guidance to a range of $3.87 to $3.93 per diluted share The midpoint of 2023 Core Operating Earnings guidance represents 4.5% year-over-year growth, excluding the collection of receivables...

Expects to be Approximately Breakeven on an Adjusted EBITDA Basis in the Second Quarter of 2023 BOSTON, May 04, 2023 (GLOBE NEWSWIRE) — DraftKings Inc. (Nasdaq: DKNG) (“DraftKings” or the “Company”) today announced its first quarter 2023 financial results. The Company also posted a first quarter 2023 business update and an earnings presentation on the Investor Relations section of its website at investors.draftkings.com. First Quarter 2023 Highlights For the three months ended March 31, 2023, DraftKings reported revenue of $770 million, an increase of 84% compared to $417 million during the same period in 2022 driven primarily by efficient acquisition of new customers, product innovation driving higher hold percentage, decreased promotional intensity in more mature states, and continued healthy customer retention. “DraftKings’...

BOCA RATON, Fla., May 04, 2023 (GLOBE NEWSWIRE) — SpringBig Holdings, Inc. (“springbig” or the “Company”) (NASDAQ: SBIG), a leading provider of SaaS-based marketing solutions, consumer mobile app experiences, and omnichannel loyalty programs to the cannabis industry, today announced its financial results for the first quarter ended March 31, 2023. “I am pleased with our execution to begin the year and with progress we are making across a number of new initiatives,” said Jeffrey Harris, CEO and Chairman of springbig. “We are managing our business efficiently with a keen eye on measured growth focused on profitability while recognizing the current macro and industry-specific realities. I am as confident as ever that our strategy is sound, with feedback from customers and partners reaffirming that we are making the right investments...

Dallas, Texas, May 04, 2023 (GLOBE NEWSWIRE) — Valhi, Inc. (NYSE: VHI) reported a net loss attributable to Valhi stockholders of $4.9 million, or $.17 per share, in the first quarter of 2023 compared to net income of $45.4 million, or $1.59 per share, in the first quarter of 2022. Net income attributable to Valhi stockholders decreased in the first quarter of 2023 compared to the first quarter of 2022 primarily due to lower operating results from our Chemicals Segment. The Chemicals Segment’s net sales were $426.3 million in the first quarter of 2023 compared to $562.9 million in the first quarter of 2022. The Chemicals Segment’s net sales comparisons were impacted by the net effects of lower sales volumes in all major markets, partially offset by higher average TiO2 selling prices. The Chemicals Segment’s TiO2 sales volumes were...